Theranostics 2020; 10(12):5181-5194. doi:10.7150/thno.44693 This issue Cite

Research Paper

A lab-on-a-disc platform enables serial monitoring of individual CTCs associated with tumor progression during EGFR-targeted therapy for patients with NSCLC

Minji Lim1,2*, Juhee Park1*, Alarice C. Lowe3#, Hyoung-oh Jeong2, Semin Lee2, Hee Chul Park4, Kyusang Lee4, Gwang Ha Kim5, Mi-Hyun Kim5✉, Yoon-Kyoung Cho1,2✉

1. Center for Soft and Living Matter, Institute for Basic Science (IBS), Ulsan 44919, Republic of Korea
2. Department of Biomedical Engineering, School of Life Sciences, Ulsan National Institute of Science and Technology (UNIST), Ulsan 44919, Republic of Korea
3. Department of Pathology, Stanford University, Stanford, CA, 94305, USA
4. Clinomics Inc., Ulsan 44919, Republic of Korea
5. Department of Internal Medicine, Pusan National University School of Medicine and Biomedical Research Institute, Pusan National University Hospital, 179, Gudeok-ro, Seo-Gu, Busan 49241, Republic of Korea
#Alarice C. Lowe's previous affiliation: Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
*These authors contributed equally to this work.

Citation:
Lim M, Park J, Lowe AC, Jeong Ho, Lee S, Park HC, Lee K, Kim GH, Kim MH, Cho YK. A lab-on-a-disc platform enables serial monitoring of individual CTCs associated with tumor progression during EGFR-targeted therapy for patients with NSCLC. Theranostics 2020; 10(12):5181-5194. doi:10.7150/thno.44693. https://www.thno.org/v10p5181.htm
Other styles

File import instruction

Abstract

Graphic abstract

Rationale: Unlike traditional biopsy, liquid biopsy, which is a largely non-invasive diagnostic and monitoring tool, can be performed more frequently to better track tumors and mutations over time and to validate the efficiency of a cancer treatment. Circulating tumor cells (CTCs) are considered promising liquid biopsy biomarkers; however, their use in clinical settings is limited by high costs and a low throughput of standard platforms for CTC enumeration and analysis. In this study, we used a label-free, high-throughput method for CTC isolation directly from whole blood of patients using a standalone, clinical setting-friendly platform.

Methods: A CTC-based liquid biopsy approach was used to examine the efficacy of therapy and emergent drug resistance via longitudinal monitoring of CTC counts, DNA mutations, and single-cell-level gene expression in a prospective cohort of 40 patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer.

Results: The change ratio of the CTC counts was associated with tumor response, detected by CT scan, while the baseline CTC counts did not show association with progression-free survival or overall survival. We achieved a 100% concordance rate for the detection of EGFR mutation, including emergence of T790M, between tumor tissue and CTCs. More importantly, our data revealed the importance of the analysis of the epithelial/mesenchymal signature of individual pretreatment CTCs to predict drug responsiveness in patients.

Conclusion: The fluid-assisted separation technology disc platform enables serial monitoring of CTC counts, DNA mutations, as well as unbiased molecular characterization of individual CTCs associated with tumor progression during targeted therapy.

Keywords: circulating tumor cells, single cell analysis, gene expression, EGFR mutation, non-small cell lung cancer


Citation styles

APA
Lim, M., Park, J., Lowe, A.C., Jeong, H.o., Lee, S., Park, H.C., Lee, K., Kim, G.H., Kim, M.H., Cho, Y.K. (2020). A lab-on-a-disc platform enables serial monitoring of individual CTCs associated with tumor progression during EGFR-targeted therapy for patients with NSCLC. Theranostics, 10(12), 5181-5194. https://doi.org/10.7150/thno.44693.

ACS
Lim, M.; Park, J.; Lowe, A.C.; Jeong, H.o.; Lee, S.; Park, H.C.; Lee, K.; Kim, G.H.; Kim, M.H.; Cho, Y.K. A lab-on-a-disc platform enables serial monitoring of individual CTCs associated with tumor progression during EGFR-targeted therapy for patients with NSCLC. Theranostics 2020, 10 (12), 5181-5194. DOI: 10.7150/thno.44693.

NLM
Lim M, Park J, Lowe AC, Jeong Ho, Lee S, Park HC, Lee K, Kim GH, Kim MH, Cho YK. A lab-on-a-disc platform enables serial monitoring of individual CTCs associated with tumor progression during EGFR-targeted therapy for patients with NSCLC. Theranostics 2020; 10(12):5181-5194. doi:10.7150/thno.44693. https://www.thno.org/v10p5181.htm

CSE
Lim M, Park J, Lowe AC, Jeong Ho, Lee S, Park HC, Lee K, Kim GH, Kim MH, Cho YK. 2020. A lab-on-a-disc platform enables serial monitoring of individual CTCs associated with tumor progression during EGFR-targeted therapy for patients with NSCLC. Theranostics. 10(12):5181-5194.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.